Navigation Links
Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
Date:6/19/2008

ion for which mucus build up and clearance is a daily problem. Our bronchiectasis program follows closely behind our work in cystic fibrosis where a phase 3 clinical trial is expected to soon close recruitment.''

Pharmaxis is developing Bronchitol as a treatment to improve mucus clearance in the lungs of patients with cystic fibrosis, bronchiectasis and other acute and chronic pulmonary conditions. The U.S. FDA has granted Bronchitol fast track status and it is designated as an orphan drug in the U.S.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

CONTACT:

Alan Robertson

Chief Executive Officer

Tel: +61-2-9454-7200

Email: alan.robertson@pharmaxis.com.au

Released through:

United States:

Brandon Lewis, Trout Group

Tel: +1-646-378-2915

Email: blewis@troutgro
'/>"/>

SOURCE Pharmaxis Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Pharmaxis Establishes Named Patient Program for Bronchitol
2. Pharmaxis Long-Term Safety Study of Bronchitol Completes
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
5. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
6. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
9. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
10. Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
11. Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  Vasomedical, Inc. (OTC BB: ... the design, manufacture and sale of medical devices and in ... Dr. Jun Ma , President and CEO ... LLP MicroCap Conference on Thursday, May 30, 2013 in ... Hotel. The Company,s presentation is scheduled to ...
(Date:5/21/2013)... Calif. , May 21, 2013   ... announced today the publication of study results involving ... CyberKnife® Robotic Radiosurgery System, the most widely used ... The study followed 304 patients for a median ... post-treatment and found that 97 percent of patients ...
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2
... NEW HAVEN, Conn., Aug. 5 Rib-X ... company focused on the,discovery and development of ... announced today that company,representatives are giving three ... Research Conference on Medicinal Chemistry, August 3-8, ...
... Aug. 5 Nexgen Spine, a leading,developer of ... disc disease, announced today that it has received ... Disc in the European,Union., "We are delighted ... mark approval," said Alastair Clemow, Ph.D., President and ...
Cached Medicine Technology:Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences 2Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences 3Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2
(Date:5/21/2013)... Journal of the Pediatric Infectious Diseases Society ... issue, which includes a consensus statement of the ... It establishes standardized definitions, measurements, and other key ... the first step as the group of international ... and resources that can improve children,s access to ...
(Date:5/21/2013)... 2013 Children with autism showed significant improvement after ... everyday items such as scents, spoons and sponges, according ... treatment known as environmental enrichment led to notable gains ... 12. Results appear online in Behavioral Neuroscience . ... assigned 28 boys to one of two groups, balanced ...
(Date:5/21/2013)... Human Reproduction & Embryology) is now the world,s leading ... expected this year, presenting a wealth of new research ... public interest. Reports from proceedings of the ESHRE congress ... , This year,s event will be held at the ... July. , The scientific programme for this year,s event ...
(Date:5/21/2013)... 21, 2013 Children using the ... Inc., experience audiological results comparable to the traditionally ... fewer complications, according to a new study. , ... Sophono’s abutment-free technology performs just as well as ... many fewer complications,” says Jim Kasic, president and ...
(Date:5/21/2013)... Adeptia, a leading provider of innovative cloud and ... the featured company in an impact report written and ... Bets on Converged Cloud Integration and Process-Orchestration Suites,” offers ... pricing, customers and competition. , “For organizations ... and process orchestration, especially when price, ease of use ...
Breaking Medicine News(10 mins):Health News:JPIDS: Releases consensus statement on research definitions for drug-resistant TB in children 2Health News:JPIDS: Releases consensus statement on research definitions for drug-resistant TB in children 3Health News:Enrichment therapy effective among children with autism, UCI study finds 2Health News:Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications 2Health News:Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications 3Health News:Adeptia Featured in Recent 451 Research Impact Report 2
... Revenue, Net ... MICROS Systems, Inc.,(Nasdaq: MCRS ), a leading supplier of information ... its,fiscal 2008 first quarter ended September 30, 2007. FINANCIAL HIGHLIGHTS, ... of $42.8 million, or 24.6%, over the ...
... wrigglers, orientation , THURSDAY, Oct. 25 (HealthDay News) -- ... worms called nematodes, say scientists who genetically manipulated some ... same sex. , The finding might give some insight ... conclusions are narrow in that they are about worms ...
... Partners with Osiris on a Phase II Trial to ... Diabetes , New York, NY October ... today a partnership with Osiris Therapeutics, Inc. (NASDAQ:OSIR) to ... immunomodulatory cell therapy product, to preserve and regenerate insulin-producing ...
... Result of Alliance with Dr. James Levine of ... Steelcase Inc. (NYSE: SCS ),a global ... workstation with an integrated treadmill, at its New,York ... from the,FitWork(TM) category of products designed to bring ...
... In its first-ever,single-topic special issue, the Harvard Heart ... advice aimed at unscrambling the mixed,messages about what ... nutrition, its recommendations include:, -- You can,t ... exercise,fruits and vegetables are the closest thing we ...
... snacking and mobile devices more appetizing than sit-down ... increasingly are,attached to portable devices such as laptops, ... eat-and-run mode. According to a,recent survey(1) conducted for ... ), nearly one in three Americans ages 18-34,has ...
Cached Medicine News:Health News:MICROS Reports Fiscal 2008 First Quarter Results 2Health News:MICROS Reports Fiscal 2008 First Quarter Results 3Health News:MICROS Reports Fiscal 2008 First Quarter Results 4Health News:MICROS Reports Fiscal 2008 First Quarter Results 5Health News:MICROS Reports Fiscal 2008 First Quarter Results 6Health News:MICROS Reports Fiscal 2008 First Quarter Results 7Health News:Worm Study Points to Sexuality's Origins 2Health News:JDRF Partners with Osiris to evaluate an immunomodulatory cell therapy product for type 1 diabetes 2Health News:Steelcase Unveils the Walkstation to Bring Healthy Habits to The Workplace 2Health News:Steelcase Unveils the Walkstation to Bring Healthy Habits to The Workplace 3Health News:All About Heart-Healthy Eating: The Harvard Heart Letter Devotes an Issue to Nutrition 2Health News:ZonePerfect(R) Survey Finds Americans Are Overfed on Technology, Underfed at the Dinner Table 2Health News:ZonePerfect(R) Survey Finds Americans Are Overfed on Technology, Underfed at the Dinner Table 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: